The British National Institute for Health and Clinical Excellence is responsible for, amongst other things, deciding which new drugs will be available on the National Health Service. It had previously ruled that the bortezomib (aka Velcade) would not be made available to bone cancer sufferers on the basis of cost. A course of the drug costs around £30,000 per annum. Now they have partially reversed this ruling after the drug's manufacturer, Janssen-Cilag, agreed to refund the NHS when the drug proved to be ineffective for a specific patient.
No comments:
Post a Comment